Your browser doesn't support javascript.
loading
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
Jonker, D J; Rosen, L S; Sawyer, M B; de Braud, F; Wilding, G; Sweeney, C J; Jayson, G C; McArthur, G A; Rustin, G; Goss, G; Kantor, J; Velasquez, L; Syed, S; Mokliatchouk, O; Feltquate, D M; Kollia, G; Nuyten, D S A; Galbraith, S.
Afiliación
  • Jonker DJ; Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Canada. Electronic address: djonker@ottawahospital.on.ca.
  • Rosen LS; Department of Oncology, Premiere Oncology, Santa Monica, USA.
  • Sawyer MB; Department of Oncology, Cross Cancer Institute, Edmonton, Canada.
  • de Braud F; Division of Clinical Pharmacology and New Drugs, Department of Medicine, European Institute of Oncology, Milan, Italy.
  • Wilding G; Department of Oncology, University of Wisconsin Carbone Cancer Center, Madison.
  • Sweeney CJ; Department of Medicine, Dana-Farber Cancer Institute, Boston, USA.
  • Jayson GC; Department of Oncology, Christie Hospital, University of Manchester, Manchester, UK.
  • McArthur GA; Department of Medical Oncology, Peter MacCallum Cancer Center, East Melbourne, Australia.
  • Rustin G; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
  • Goss G; Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Canada.
  • Kantor J; Research and Development, Bristol-Myers Squibb, Princeton, USA.
  • Velasquez L; Research and Development, Bristol-Myers Squibb, Princeton, USA.
  • Syed S; Research and Development, Bristol-Myers Squibb, Princeton, USA.
  • Mokliatchouk O; Research and Development, Bristol-Myers Squibb, Princeton, USA.
  • Feltquate DM; Research and Development, Bristol-Myers Squibb, Princeton, USA.
  • Kollia G; Research and Development, Bristol-Myers Squibb, Princeton, USA.
  • Nuyten DSA; Research and Development, Bristol-Myers Squibb, Princeton, USA.
  • Galbraith S; Research and Development, Bristol-Myers Squibb, Princeton, USA.
Ann Oncol ; 22(6): 1413-1419, 2011 Jun.
Article en En | MEDLINE | ID: mdl-21131369
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Triazinas / Receptores de Factores de Crecimiento de Fibroblastos / Inhibidores de la Angiogénesis / Receptores de Factores de Crecimiento Endotelial Vascular / Alanina / Neoplasias / Antineoplásicos Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2011 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Triazinas / Receptores de Factores de Crecimiento de Fibroblastos / Inhibidores de la Angiogénesis / Receptores de Factores de Crecimiento Endotelial Vascular / Alanina / Neoplasias / Antineoplásicos Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2011 Tipo del documento: Article